Kinase Inhibitor for Cancer Therapy
Cancer is one of the leading causes of death worldwide, yet considerable efforts are still required to make this pathology curable. Despite the limits of available approaches, kinase inhibitors have marked a turning point in the treatment of different types of tumors. This class of compounds is the...
Uloženo v:
| Médium: | Online |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Témata: | |
| On-line přístup: | ONIX_20240704_9783725812905_147 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1869520632903892992 |
|---|---|
| collection | Directory of Open Access Books |
| description | Cancer is one of the leading causes of death worldwide, yet considerable efforts are still required to make this pathology curable. Despite the limits of available approaches, kinase inhibitors have marked a turning point in the treatment of different types of tumors. This class of compounds is the first oral targeted therapy approved for neoplasia, and about 30 compounds have entered the market in the last five years. Kinase inhibitors include small molecules and monoclonal antibodies and are endowed with fewer side effects than classical antitumor agents. The potential for application of this class of drugs is substantial, and this Special Issue focuses on the discovery and development of kinase inhibitors in terms of in silico studies, synthesis and identification of new compounds, drug delivery, formulation studies, and biological and pharmacokinetic evaluation. |
| format | Online |
| id | doab-20.500.12854ir-139351 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1393512024-07-04T09:45:20Z Kinase Inhibitor for Cancer Therapy Musumeci, Francesca JAK synthesis kinase inhibitory activity pharmacological uses binding mode/interactions choline kinase lipid metabolism cisplatin lung tumors combinatorial chemotherapy glioblastoma Src pyrazolo [3,4-d]pyrimidine scaffold EGFR multiple myeloma tyrosine kinase treatment ibrutinib gastric cancer kinase inhibitor ALK targeted therapy JNK3 fragment saturation transfer difference NMR X-ray crystallography breast cancer nanomedicine PI3K? poloxamers polymeric nanoparticles TPGS zanubrutinib anthracycline drug resistance aldo-keto reductase 1C3 ABC drug efflux transporter Hsp90 inhibitor co-chaperone heterocycle molecules anticancer agents heat shock proteins ER stress PERK UPR kinase inhibitor cancer diabetes small molecule structure–activity-relationship (SAR) MCL ROR1 small molecules apoptosis AKT1 kinase inhibitors acute myeloid leukemia rare disease molecular modeling molecular docking similarity search MD simulation computer-aided drug discovery cutaneous T-cell lymphoma TWIST1 erufosine curcumin synergy nanotechnology 3D tissue culture 3D tumor model tumor spheroids drug screening preclinical study tyrosine kinase inhibitors innate immunity thyroid cancer tumor-associated macrophages cytokines c-Src/Abl dual inhibitors pyrazolo[3,4-d]pyrimidines ADME antiproliferative activity childhood cancer kinases chemical inhibitors clinical trials dasatinib CML HIV-1 CMV HIV functional cure memory-like NK cells ?? T cells anti-aging senolytic NSCLC KAN0441571C erlotinib TTP rigosertib ON-01910.Na cancer therapy kinase allosteric inhibition Plk1 Ras JNK PI3K/Akt microtubule-destabilizing agents stress-signaling pathways aptamer MNK1 therapeutic target non-small cell lung cancer antitumor 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine (DMAT) derivatives protein kinase CK2 protein kinase PIM-1 dual protein kinase inhibitors antitumor activity autophagy hepatocellular carcinoma EGFR/PI3K/AKT/mTOR signaling animal models n/a thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSD Molecular biology Cancer is one of the leading causes of death worldwide, yet considerable efforts are still required to make this pathology curable. Despite the limits of available approaches, kinase inhibitors have marked a turning point in the treatment of different types of tumors. This class of compounds is the first oral targeted therapy approved for neoplasia, and about 30 compounds have entered the market in the last five years. Kinase inhibitors include small molecules and monoclonal antibodies and are endowed with fewer side effects than classical antitumor agents. The potential for application of this class of drugs is substantial, and this Special Issue focuses on the discovery and development of kinase inhibitors in terms of in silico studies, synthesis and identification of new compounds, drug delivery, formulation studies, and biological and pharmacokinetic evaluation. 2024-07-04T09:45:17Z 2024-07-04T09:45:17Z 2024 book ONIX_20240704_9783725812905_147 9783725812905 9783725812899 https://directory.doabooks.org/handle/20.500.12854/139351 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/9349 https://mdpi.com/books/pdfview/book/9349 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-1289-9 10.3390/books978-3-7258-1289-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725812905 9783725812899 518 open access |
| spellingShingle | JAK synthesis kinase inhibitory activity pharmacological uses binding mode/interactions choline kinase lipid metabolism cisplatin lung tumors combinatorial chemotherapy glioblastoma Src pyrazolo [3,4-d]pyrimidine scaffold EGFR multiple myeloma tyrosine kinase treatment ibrutinib gastric cancer kinase inhibitor ALK targeted therapy JNK3 fragment saturation transfer difference NMR X-ray crystallography breast cancer nanomedicine PI3K? poloxamers polymeric nanoparticles TPGS zanubrutinib anthracycline drug resistance aldo-keto reductase 1C3 ABC drug efflux transporter Hsp90 inhibitor co-chaperone heterocycle molecules anticancer agents heat shock proteins ER stress PERK UPR kinase inhibitor cancer diabetes small molecule structure–activity-relationship (SAR) MCL ROR1 small molecules apoptosis AKT1 kinase inhibitors acute myeloid leukemia rare disease molecular modeling molecular docking similarity search MD simulation computer-aided drug discovery cutaneous T-cell lymphoma TWIST1 erufosine curcumin synergy nanotechnology 3D tissue culture 3D tumor model tumor spheroids drug screening preclinical study tyrosine kinase inhibitors innate immunity thyroid cancer tumor-associated macrophages cytokines c-Src/Abl dual inhibitors pyrazolo[3,4-d]pyrimidines ADME antiproliferative activity childhood cancer kinases chemical inhibitors clinical trials dasatinib CML HIV-1 CMV HIV functional cure memory-like NK cells ?? T cells anti-aging senolytic NSCLC KAN0441571C erlotinib TTP rigosertib ON-01910.Na cancer therapy kinase allosteric inhibition Plk1 Ras JNK PI3K/Akt microtubule-destabilizing agents stress-signaling pathways aptamer MNK1 therapeutic target non-small cell lung cancer antitumor 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine (DMAT) derivatives protein kinase CK2 protein kinase PIM-1 dual protein kinase inhibitors antitumor activity autophagy hepatocellular carcinoma EGFR/PI3K/AKT/mTOR signaling animal models n/a thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSD Molecular biology Kinase Inhibitor for Cancer Therapy |
| title | Kinase Inhibitor for Cancer Therapy |
| title_full | Kinase Inhibitor for Cancer Therapy |
| title_fullStr | Kinase Inhibitor for Cancer Therapy |
| title_full_unstemmed | Kinase Inhibitor for Cancer Therapy |
| title_short | Kinase Inhibitor for Cancer Therapy |
| title_sort | kinase inhibitor for cancer therapy |
| topic | JAK synthesis kinase inhibitory activity pharmacological uses binding mode/interactions choline kinase lipid metabolism cisplatin lung tumors combinatorial chemotherapy glioblastoma Src pyrazolo [3,4-d]pyrimidine scaffold EGFR multiple myeloma tyrosine kinase treatment ibrutinib gastric cancer kinase inhibitor ALK targeted therapy JNK3 fragment saturation transfer difference NMR X-ray crystallography breast cancer nanomedicine PI3K? poloxamers polymeric nanoparticles TPGS zanubrutinib anthracycline drug resistance aldo-keto reductase 1C3 ABC drug efflux transporter Hsp90 inhibitor co-chaperone heterocycle molecules anticancer agents heat shock proteins ER stress PERK UPR kinase inhibitor cancer diabetes small molecule structure–activity-relationship (SAR) MCL ROR1 small molecules apoptosis AKT1 kinase inhibitors acute myeloid leukemia rare disease molecular modeling molecular docking similarity search MD simulation computer-aided drug discovery cutaneous T-cell lymphoma TWIST1 erufosine curcumin synergy nanotechnology 3D tissue culture 3D tumor model tumor spheroids drug screening preclinical study tyrosine kinase inhibitors innate immunity thyroid cancer tumor-associated macrophages cytokines c-Src/Abl dual inhibitors pyrazolo[3,4-d]pyrimidines ADME antiproliferative activity childhood cancer kinases chemical inhibitors clinical trials dasatinib CML HIV-1 CMV HIV functional cure memory-like NK cells ?? T cells anti-aging senolytic NSCLC KAN0441571C erlotinib TTP rigosertib ON-01910.Na cancer therapy kinase allosteric inhibition Plk1 Ras JNK PI3K/Akt microtubule-destabilizing agents stress-signaling pathways aptamer MNK1 therapeutic target non-small cell lung cancer antitumor 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine (DMAT) derivatives protein kinase CK2 protein kinase PIM-1 dual protein kinase inhibitors antitumor activity autophagy hepatocellular carcinoma EGFR/PI3K/AKT/mTOR signaling animal models n/a thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSD Molecular biology |
| topic_facet | JAK synthesis kinase inhibitory activity pharmacological uses binding mode/interactions choline kinase lipid metabolism cisplatin lung tumors combinatorial chemotherapy glioblastoma Src pyrazolo [3,4-d]pyrimidine scaffold EGFR multiple myeloma tyrosine kinase treatment ibrutinib gastric cancer kinase inhibitor ALK targeted therapy JNK3 fragment saturation transfer difference NMR X-ray crystallography breast cancer nanomedicine PI3K? poloxamers polymeric nanoparticles TPGS zanubrutinib anthracycline drug resistance aldo-keto reductase 1C3 ABC drug efflux transporter Hsp90 inhibitor co-chaperone heterocycle molecules anticancer agents heat shock proteins ER stress PERK UPR kinase inhibitor cancer diabetes small molecule structure–activity-relationship (SAR) MCL ROR1 small molecules apoptosis AKT1 kinase inhibitors acute myeloid leukemia rare disease molecular modeling molecular docking similarity search MD simulation computer-aided drug discovery cutaneous T-cell lymphoma TWIST1 erufosine curcumin synergy nanotechnology 3D tissue culture 3D tumor model tumor spheroids drug screening preclinical study tyrosine kinase inhibitors innate immunity thyroid cancer tumor-associated macrophages cytokines c-Src/Abl dual inhibitors pyrazolo[3,4-d]pyrimidines ADME antiproliferative activity childhood cancer kinases chemical inhibitors clinical trials dasatinib CML HIV-1 CMV HIV functional cure memory-like NK cells ?? T cells anti-aging senolytic NSCLC KAN0441571C erlotinib TTP rigosertib ON-01910.Na cancer therapy kinase allosteric inhibition Plk1 Ras JNK PI3K/Akt microtubule-destabilizing agents stress-signaling pathways aptamer MNK1 therapeutic target non-small cell lung cancer antitumor 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine (DMAT) derivatives protein kinase CK2 protein kinase PIM-1 dual protein kinase inhibitors antitumor activity autophagy hepatocellular carcinoma EGFR/PI3K/AKT/mTOR signaling animal models n/a thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSD Molecular biology |
| url | ONIX_20240704_9783725812905_147 |